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Abstract: Over the past three decades, survival in advanced non–
small-cell lung cancer (NSCLC) clinical trials has doubled with an 
increase in 1-year survival from 25% to 50 to 55%. This has been 
mainly attributed to improvements in systemic therapy. Although 
modern ﬁrst-line chemotherapy regimens have more favorable toxicity 
proﬁles, a statistically signiﬁcant improvement in overall survival has 
not been demonstrated in existing meta-analyses of second-generation 
versus third-generation combinations. Moreover, pivotal trials demon-
strating statistically signiﬁcant survival superiority of third-generation 
regimens are consistently not reproducible even for nonsquamous pop-
ulations using pemetrexed–platinum combinations. As enhancement in 
the efﬁcacy of ﬁrst-line systemic therapy in patients without identiﬁ-
able driver mutations is questionable, other factors are discussed that 
explain the doubling of 1-year survival reported in clinical trials. These 
factors include second-line or third-line therapy, maintenance chemo-
therapy, performance status selection, stage migration, sex migration, 
improved treatment of brain metastases, and better palliative care.
Key Words: Non–small-cell lung cancer, Palliative chemotherapy, 
Critical review.
(J Thorac Oncol. 2015;10: 1523–1531)
Lung cancer is the leading cause of cancer deaths in both males and females with an estimated 224,000 new cases 
and 159,000 deaths in the United States in 2014 and 26,100 
new cases and 20,500 deaths in Canada in 2014.1,2 Eighty-ﬁve 
percent of lung cancer cases are non–small-cell lung cancer 
(NSCLC), and because a large fraction of NSCLC patients are 
diagnosed with advanced disease and many patients relapse 
from earlier stage disease, more than 80% of this patient popu-
lation are potential beneﬁciaries of palliative systemic therapy.3
Palliative ﬁrst-line chemotherapy has been shown to 
improve both quality of life and survival in advanced NSCLC 
patients.3–5 Practice guidelines exist for systemic therapy 
administration with the intent that most advanced NSCLC 
patients receive some form of palliative anticancer drug treat-
ment.6 However, when population-based data are examined, 
less than half of the advanced NSCLC patient population 
receive any systemic therapy in United States7–10 and Canada.11
Over the past 30 years, there has been considerable 
improvement in overall survival (OS) in advanced NSCLC 
as reported in large randomized controlled trials (Table 1). 
The median survival and 1-year survival with early platinum 
combinations were approximately 7 months and 25%, respec-
tively, whereas with the most recent generation of platinum 
combinations, the median survival has increased to 12 to 13 
months, and the 1-year survival is typically 50% to 55%.12 
This impressive doubling of median survival and 1-year sur-
vival is similar to the doubling of survival in colorectal can-
cer.13 For both diseases, the improvement is typically ascribed 
to “the introduction of new drugs and patient selection based 
on the recognition that different histological subtypes and 
driver mutations determine the biology of these malignancies, 
and predict drug efﬁcacy.”12
This review examines the evolution of ﬁrst-line chemo-
therapy for advanced NSCLC who are not known to harbor 
a targetable mutation and attempts to quantify the contribu-
tion of improved efﬁcacy of ﬁrst-line chemotherapy to the 
observed doubling of OS since the introduction of platinum-
based regimens in 1977.16 The impact of other factors that 
have contributed to improvement of OS in clinical trials are 
discussed including second-line or third-line therapy, mainte-
nance chemotherapy, performance status (PS) selection, stage 
migration, sex migration, improved treatment of brain metas-
tases, and better palliative care (Table 2).
HISTORY OF THE EVOLUTION OF 
CHEMOTHERAPY FOR ADVANCED NSCLC
First-Generation Chemotherapy 
Regimens (1960–1980s)
The deﬁning characteristic of the ﬁrst-generation regi-
mens was the use of alkylating agents. In 1948, Karnofsky 
et al.17 published one of the ﬁrst reports evaluating the efﬁ-
cacy of chemotherapy in advanced bronchogenic carcinoma. 
He reported improvement in symptoms and Karnofsky 
Performance Score with nitrogen mustard. However, the 
median duration of beneﬁt was less than a month. In the 1960s, 
the activity of a number of single agents was explored, such as 
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cyclophosphamide, vinblastine, and methotrexate. A series of 
randomized studies from the Veterans’ Administration hospi-
tals compared alkylating agents with an inert compound and 
showed a “slight” favorable effect on survival for nitrogen 
mustards in squamous cell carcinomas and for cyclophos-
phamide in small-cell lung cancer.18 The overall effect on sur-
vival was “not remarkable,” and a retrospective review of the 
sixth protocol (nitrogen mustard vs. intravenous cyclophos-
phamide) showed improvement in the roentgenograms in less 
than 10% of patients.
In the 1970s, the recognition that mechlorethamine, 
vincristine, procarbazine, and prednisone chemotherapy 
could cure Hodgkin lymphoma19 led to an evaluation of 
alkylator-based mechlorethamine, vincristine, procarbazine, 
and prednisone–like regimens in the treatment of lung can-
cer such as methotrexate, adriamycin, cyclophosphamide, and 
lomustine15 and cyclophosphamide, doxorubicin, methotex-
ate, and procarbazine14 (Table 1). Unfortunately, the trials 
and meta-analyses of alkylating agents compared with a no 
chemotherapy arm showed a trend toward a detrimental effect 
on survival for NSCLC (hazard ratio, 1.26; 95% conﬁdence 
interval [CI], 0.96–1.66).20
Second-Generation Chemotherapy 
Regimens (1980s–1995)
Second-generation regimens emerged in the mid-1980s 
based on the addition of a platinum agent combined with 
companion drugs that included vindesine, vinblastine, etopo-
side, mitomycin, or ifosfamide. Objective response rates were 
usually in the range of 20% to 30% with 10% to 20% 1-year 
survival. These were the ﬁrst regimens to show a signiﬁcant 
improvement in OS and quality of life. In one of the earli-
est trials comparing cisplatin-based regimens with supportive 
care, Rapp et al.5 evaluated cyclophosphamide, doxorubicin, 
and cisplatin; vindesine and cisplatin; and best supportive 
care (BSC) in advanced NSCLC population. The median 
OS of vindesine and cisplatin was 32.6 weeks; 24.7 weeks 
with cyclophosphamide, doxorubicin, and cisplatin; and 17 
weeks with BSC. Of note, many second-generation regimens 
included alkylating agents like cyclophosphamide and ifos-
famide or mitomycin, which have been shown to have a detri-
mental effect on survival.20,21
The best second-generation regimens combined plati-
num with a plant alkaloid or a podophylotoxin. In 1986, 
Finkelstein et al.21 reviewed the extensive experience of the 
Eastern Cooperative Oncology Group (ECOG) phase III tri-
als. There was no marked differences in outcome among the 
regimens tested, with a median survival of 23.5 weeks and 
1-year survival of 19%. The etoposide–platinum combina-
tion had the highest proportion of 1-year survivors at 25%. 
Because of this effect on survival plus manageable toxicity 
of this regimen, etoposide plus cisplatin was chosen as the 
TABLE 1. Metastatic Non–Small-Cell Lung Cancer (NSCLC) Survival Landmarks
Era Chemotherapy Median Survival (mo) One-Year Survival (%) Two-Year Survival (%)
BSC, 1970–1980 4–5 15 2–3
1st generation, 1970–1980 1960s single agents:
1.Nitrogen mustard
2.Cyclophosphamide
3.Vinblastine
4.Methotrexate
5.doxorubicin
1970s MOPP-like regimens:
1.CAMP14
2.MACC15
4–5 10–15 2–3
2nd generation, 1980–1995 Cisplatin plus:
1.Vinblastine
2.Vindesine
3.Etoposide
4.Mitomycin
5.Ifosfamide
6.doxorubicin/cyclophosphamide
7 25 6–7
3rd generation, 1995–2005 Cisplatin or carboplatin plus:
1. Vinorelbine
2. Paclitaxel
3. Docetaxel
4. Gemcitabine
5. Pemetrexed
8–10 40 12–15
3rd generation, 2005+ 12–13 50–55 20–25
BSC, best supportive care; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; CAMP, cyclophosphamide, doxorubicin, methotexate, and procarbazine; MACC, 
methotrexate, adriamycin, cyclophosphamide, and lomustine.
TABLE 2. Reasons Why Survival Has Improved in Advanced 
Non–Small-Cell Lung Cancer (NSCLC) Clinical Trials
1. Third-generation regimens are slightly better
2. Second-line and third-line chemotherapy
3. Maintenance therapy
4. Performance status selection
5. Stage migration
6. Sex migration
7. Better treatment for brain metastases
8. Better palliative care
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reference regimen for ECOG in moving forward to test the 
next generation of regimens.22
Meta-analyses of these trials of cisplatin-based chemo-
therapy versus BSC in advanced NSCLC showed a reduction 
in the risk of death by 27% (hazard ratio, 0.73; p < 0.0001), 
translating to an improved 1-year survival from 15% to 25% 
and an improvement in median OS from 5 to 7 months.20 
Moreover, it was found to relieve symptoms, improve quality 
of life, and be cost effective.
Third-Generation Chemotherapy 
Regimens (1995–Present)
The third-generation regimens include platinum plus a 
“modern” companion drug (vinorelbine, paclitaxel, docetaxel, 
gemcitabine, or pemetrexed). These regimens are widely 
accepted as more efﬁcacious for improving survival com-
pared with second-generation regimens. Indeed, there are piv-
otal randomized trials comparing second-generation regimens 
with each of the third-generation companion drugs plus a plat-
inum backbone that declare a statistically signiﬁcant survival 
improvement for the new agents (Table 3).22–25 These pivotal 
trials were widely used for marketing purposes with consider-
able success.
One of the earliest pivotal trials that facilitated the tran-
sition from second-generation to third-generation trials was 
by Le Chevalier et al. comparing cisplatin–vinorelbine versus 
cisplatin–vindesine versus vinorelbine, which showed higher 
response rates (30% vs. 19%, p = 0.02 vs. 14%, p < 0.001) and 
OS (40 vs. 32 wk, p = 0.04 vs. 31 weeks, p = 0.01).23 In North 
America, the ECOG study of the reference regimen of cis-
platin–etoposide versus two schedules of cisplatin–paclitaxel 
showed a survival superiority trend in both paclitaxel arms 
and a statistically signiﬁcant survival improvement when the 
paclitaxel arms were combined.22 The toxicities and quality of 
life scores were similar across all three regimens. Use of sec-
ond-generation regimens for ﬁrst-line treatment of advanced 
NSCLC became passé.
The conﬁdence that third-generation regimens were 
superior to second-generation regimens was further enhanced 
by the increased OS times reported in clinical trials after 2005. 
The median and 1-year survival outcomes increased from 8 
months and 35%26 to 10 to 12 months and 45% to 50% in the 
modern trials even if a targeted agent or maintenance therapy 
was not used with the third-generation regimen.27–29
The Seeds of Doubt for Improved Survival 
Efficacy of Modern Chemotherapy Regimens
Meta-analyses of second-generation versus third-gener-
ation regimens have not shown a statistically signiﬁcant sur-
vival improvement.30,31 Baggstrom et al.30 examined 12 trials 
comparing third-generation with second-generation regimens 
including 3995 patients, and the 1-year survival numeric dif-
ference was 6% (95% CI: 2%, 10%). Moreover, 25% of the 
second-generation arms in these studies contained mitomycin 
and/or ifosfamide, which may impede survival improvement. 
Notably, no pemetrexed trials were included in the second-
generation versus third-generation meta-analyses.
A selected number of trials demonstrated a survival 
beneﬁt comparing second-generation and third-generation 
chemotherapy regimens (Table 3). A wider view of so-called 
“negative” trials, however, has not been as prominently high-
lighted in NSCLC literature (Table 4).32–37 These latter tri-
als suggest no signiﬁcant survival beneﬁt when comparing 
second-generation versus third-generation regimens or early-
generation versus later-generation regimens. Moreover, a 
superior regimen failed to emerge from numerous large tri-
als comparing third-generation regimens.26,38–42 The survival 
beneﬁt of “modern” chemotherapy for NSCLC may not be 
different than “older” regimens, once alkylating agents and 
mitomycin are eliminated.
After the publication of ECOG 1594 in 2002,27 it was 
declared that there was a plateau reached for chemotherapy 
efﬁcacy.43 However, with the selection of chemotherapy based 
on histologic subtype reported by Scagliotti et al.27,44 showing 
an improvement in OS in a subset of patients with nonsqua-
mous histology with cisplatin–pemetrexed compared with 
cisplatin–gemcitabine, it became widely accepted that this 
stalemate had been broken.3,12
The trial by Scagliotti et al.27 that concluded cisplatin 
and pemetrexed was superior for patients with nonsquamous 
histology was based on a nonstratiﬁed subset (the stratiﬁca-
tion parameter was for histologic vs. cytologic biopsy, not 
TABLE 3. Pivotal Trials of Second Versus Third-Generation Platinum-Doublet Regimens
First author Treatment No. of Randomized ORR (%) mOS (mo) P Value One-Year Survival (%)
Le Chevalier23 Cis, vinorelbine 206 30 10 0.04 34
Cis, vindesine 200 19 8 27
Vinorelbine 206 14 8
Bonomi et al.22 Cis, high-dose Taxola 191 27 9.9 0.048 39
Cis, low-dose Taxola 190 12 7.6
Cis, etoposide 183 32
Kubota et al.24 Cis, docetaxel 151 37 11.3 0.014 48
Cis, vindesine 151 21 9.6 41
Rudd25 Carbo, gemcitabine 212 42 10 0.008 40
Cis, ifos, mitomycin 210 41 7.6 30
aHigh-dose and low-dose paclitaxel (Taxol) arms were combined for analysis.
ORR, objective response rate; mOS, median overall survival; cis, cisplatin; carbo, carboplatin; ifos, ifosfamide.
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histologic subtype). However, four randomized trials compar-
ing platinum–pemetrexed with other platinum doublets are 
all negative for signiﬁcant OS differences (Table 5).45–48 The 
trial by Grønberg et al.45 of carboplatin–pemetrexed versus 
carboplatin–gemcitabine conducted in a patient population 
unselected by histology showed no evidence of pemetrexed 
superiority in the nonsquamous subset. Three prospective trials 
tested the hypothesis of pemetrexed–platinum superiority by 
randomly assigning only patients with nonsquamous disease 
to carboplatin–pemetrexed versus carboplatin–docetaxel,46 
cisplatin–pemetrexed versus cisplatin–oral vinorelbine,47 and 
cisplatin–-docetaxel versus cisplatin–pemetrexed.48 All these 
prospective trials testing pemetrexed superiority for nonsqua-
mous NSCLC failed to conﬁrm this hypothesis although it is 
acknowledged that these trials are not powered to demonstrate 
small differences in survival.
Two other trials compared platinum and pemetrexed with 
carboplatin and paclitaxel in nonsquamous cancers, but the inter-
pretation is complicated by the inclusion of bevacizumab.49,50 
 The large PointBreak study compared carboplatin–pemetrexed– 
bevacizumab followed by maintenance pemetrexed–bevaci-
zumab versus carboplatin–paclitaxel–bevacizumab followed 
TABLE 4. Nonconfirmatory Clinical Trials of Second Versus Third-Generation Platinum-Doublet Regimens
First Author Treatment No. Randomized ORR (%) mOS (mo) P Value One-Year Survival (%)
Giaccone et al.32 Cis, paclitaxel 155 41 9.7 0.971 43
Cis, teniposide 162 28 9.9 41
Baldini et al.33 Carbo, vinorelbine 43 14 7.9 NR 16
Cis, vindesine, mitomycin 49 14 8.4 18
Cis, ifos, vinorelbine 48 17 8.8 15
Cardenal et al.34 Cis, gemcitabine 69 41 8.7 0.18 32
Cis, etoposide 64 22 7.2 27
Crino et al.35 Cis, gemcitabine 155 38 8.6 0.877 33
Cis, mitomycin, ifos 152 26 9.6 34
Gebbia et al.36 Cis, vinorelbine 122 39 7 0.898 15
Cis, vindesine, mitomycin 125 42 8 15
Belani et al.37 Carbo, paclitaxel 190 23 7.7 0.086 32
Cis, etoposide 179 15 9.0 37
ORR, objective response rate; mOS, median overall survival; cis, cisplatin; carbo, carboplatin; ifos, ifosfamide; NR, not reported.
TABLE 5. Randomized Trials of Platinum–Pemetrexed Versus Other Platinum Doublets
First author Treatment No. randomized ORR (%) mOS (mo) P Value 1-yr survival (%)
Scagliotti et al.27 Cis, gemcitabine vs. 863 NR 10.3 95% CI: 42
Cis, pemetrexed 862 NR 10.3 0.84–1.05 44
Nonsquamous:
Cis, gemcitabine 488 NR 11.8 0.03 (subset analysis) NR
Cis, pemetrexed 512 NR 10.4 NR
Grønberg et al.45 Carbo, gemcitabine vs. 221 NR 7.0 0.63 NR
Carbo, pemetrexed 225 NR 7.3 NR
Nonsquamous:
Carbo, gemcitabine 167 NR 7.5 0.77 (subset analysis) NR
Carbo, pemetrexed 162 NR 7.8 NR
Rodrigues-Pereira et al46 Carbo, pemetrexed vs. 128 34 14.9 0.934 NR
Carbo, docetaxel 132 23 14.7 NR
All nonsquamous
Bennouna et al.47 Cis, vinorelbine vs. 100 23 10.6 NR NR
Cis, pemetrexed* 51 26 10.8 NR
All nonsquamous
Kim et al.48 Cis, docetaxel vs. 72 33.3 28.0 NR NR
77 31.2 19.7Cis, pemetrexed NR
All nonsquamous
*All nonsquamous histology.
CI, conﬁdence interval; ORR, objective response rate; mOS, median overall survival; cis, cisplatin; carbo, carboplatin; ifos, ifosfamide; NR, not reported.
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by maintenance bevacizumab.49 A recent systematic review 
published in the Journal of Thoracic Oncology concluded that 
the outcomes between taxane and nontaxane regimens when 
given in combination with bevacizumab for patients with 
nonsquamous NSCLC are comparable.51 This result provides 
some legitimacy for a comparison of the chemotherapy back-
bone regimens, which showed no difference in OS. A further 
trial by Zinner et al.50 compared carboplatin–pemetrexed with 
pemetrexed maintenance versus carboplatin–paclitaxel plus 
bevacizumab with bevacizumab maintenance, and the survival 
outcome was the same. The consistency of all these trials to 
show no evidence of survival superiority for platinum–peme-
trexed versus other platinum doublets make it questionable 
whether the stalemate in the evolution of improved efﬁcacy of 
ﬁrst-line therapy for NSCLC has been broken with platinum–
pemetrexed for nonsquamous histology.
An interesting observation over the years has been the 
continuous process of one ﬁrst-line NSCLC chemotherapy 
regimen competing for popularity and market share with a 
new combination. This may be referred to as the ‘life/death 
cycle’ of a novel NSCLC chemotherapy regimen (Fig. 1). If a 
bona ﬁde improvement in survival efﬁcacy was chosen as the 
motivation for switching regimens, the scientiﬁc content of 
the process would be in doubt. Factors including convenience, 
toxicity, and economics of reimbursement clearly influence 
patterns of care.
REASONS FOR IMPROVED OS REPORTED IN 
ADVANCED NSCLC CLINICAL TRIALS
If the seeds of doubt as to the veracity of the improve-
ment of ﬁrst-line chemotherapy for advanced NSCLC are to 
be taken seriously, it is necessary to explain in a satisfactory 
fashion the observed improvement in survival in advanced 
NSCLC trials reported over the past 30 years. The milestone 
of median survival formerly was 7 months and currently is 
12 to 13 months, and 1-year survival doubled from 25% to 
50% to 55% (Table 1). This large increase must be accounted 
for, and there are numerous factors at play, and although all 
are modest in size, when taken together, they account for the 
observed increase in survival.
True Superiority of Third-Generation Regimens
The most often stated reason for improved OS in 
advanced NSCLC patients in clinical trials is superior ﬁrst-line 
chemotherapy. The meta-analysis by Baggstrom et al.30 reported 
a 6% improvement in 1-year survival rate (95% CI, 2–10%). 
Although not statistically signiﬁcant, this numeric value is our 
best estimation of increase in survival of third-generation regi-
mens. Much of the improvement remains unexplained.
Systemic Therapy After First-Line Chemotherapy
Receipt of second-line systemic therapy signiﬁcantly 
improves OS of NSCLC patients. Docetaxel was shown to 
improve OS and 1-year survival compared with BSC (median 
7.5 vs. 4.6 mo; 1-year survival, 29% vs. 19%).52 Pemetrexed 
was shown to have similar efﬁcacy (median OS, 8 mo in both 
arms) and lower toxicity than that of docetaxel in a phase III 
trial of 571 patients.53 Erlotinib improved OS compared with 
BSC (median 6.7 vs. 4.7 mo) in unselected patients who had 
received one or two prior chemotherapy regimens.54 Because 
epidermal growth factor receptor and anaplastic lymphoma 
kinase testing have been only recently mandated as routine, in 
unselected patient clinical trial populations, the survival ben-
eﬁt of erlotinib on epidermal growth factor receptor mutation 
positive patients would be considerable.
Maintenance treatment administers further systemic 
therapy after a ﬁrst-line platinum combination to a selected 
population without progressive disease and good PS. 
Maintenance treatment improves survival particularly when 
patients fail to receive second-line therapy.55 Switch main-
tenance strategy administers pemetrexed in nonsquamous 
cell histology56 or erlotinib57 for patients who have stable 
disease or response after four cycles of a platinum-doublet. 
“Continuation maintenance” with pemetrexed may be con-
sidered in patients with nonsquamous cell histology who 
have stable disease or response to four cycles of cisplatin and 
pemetrexed.58 Because of the selection of favorable patients 
to receive maintenance therapy, survival outcomes reported 
in these trials is longer. The median OS beneﬁt from main-
tenance therapy ranged from 1 month with erlotinib57 to 2.9 
months with pemetrexed “continuation maintenance.”58
Performance Status Selection
Patient selection has been in evolution since the advent 
of the ﬁrst clinical lung cancer trials. In the early years, 
the inclusion criteria were broad allowing ECOG PS 0–4 
patients.14–16 In the NCIC BR5 trial, which enrolled patients 
from 1983 to 1986, 40% of the patients were ECOG PS 2 or 
higher.5 When Bonomi et al.22 reviewed the ECOG trials, it 
was observed that ECOG PS 2 had more toxicity, and it was 
difﬁcult to show that they showed beneﬁt from innovations 
of treatment. The last attempt to include PS 2 patients in an 
ECOG trial was in ECOG 1594 by Schiller et al.26 According 
to the original design, patients with an ECOG PS of 2 and 
those with a PS of 0 or 1 were eligible. However, after 66 
patients with a PS of 2 had been enrolled, the study design was 
FIGURE 1. Life/death cycle of a first-line non–small-cell lung 
cancer (NSCLC) chemotherapy regimen.
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amended to include only patients with PS of 0 and 1 because 
of the high rate or serious adverse events in the PS 2 cohort. 
The median survival among patients with a PS of 0 was 10.8 
months, when compared with 7.1 months for patients with a 
PS of 1 and 3.9 months for those with a PS of 2 (p < 0.0001).26
When examining more contemporary trials it is clear that 
PS 2 patients still do worse, and their inclusion decreases the sur-
vival of the entire cohort. In the Grønberg et al.45 trial, the median 
OS for the carboplatin–pemetrexed PS 0–1 patients versus PS 2 
was 8.7 months compared with 4.3 months and for carboplatin–
gemcitabine it was 7.7 months compared with 5.1 months.
Generally, cooperative groups and the pharmaceuti-
cal industry followed suit, and ECOG PS 2 patients were 
excluded from most recent trials of chemotherapy. On the one 
hand, it is understandable why investigation of a new drug 
therapy should minimize harm and allow a better chance to 
show a signal of improved survival by randomizing good risk 
patients. On the other hand, we must look wistfully over our 
shoulder at the lost opportunity of guidance from clinical tri-
als that actually reflect the patient populations we see in the 
clinic and treat with carefully considered practice guidelines.6
It is obviously inappropriate to make across trial com-
parisons where PS selection is increasingly restricted and 
attribute better survival outcomes solely to an improvement 
in chemotherapy.
Stage Migration
Stage migration occurs after the introduction of a more 
sensitive staging modality, which results in assignment of 
higher stage than with conventional staging alone. This was 
shown by Feinstein et al.,59 with the use of technetium bone 
scanning, computed tomography and ultrasonography, when it 
was noted that patients with “early-stage” disease were shifted 
into a more advanced stage, artiﬁcially inflating survival rates. 
The “Will Rogers Phenomenon” removes the poorer prog-
nostic group from the earlier stages and reallocates them 
to a higher stage, thereby improving the prognosis of both 
groups.59 In 2004, ASCO recommended positron emission 
tomography (PET) as a staging modality in patients with 
operable and locally advanced NSCLC on computed tomog-
raphy-scan.60 Data from Surveillance, Epidemiology, and End 
Results Program from 1998 to 2003 showed an increase in use 
of PET scanning from 2% to 47%.61 Although there was an 
improvement in stage-speciﬁc survival, no OS improvement 
for the entire group was seen, indicating the existence of stage 
migration. The stage migration caused by PET was associated 
with an increase in the 2-year survival from 12% to 15% in the 
advanced stage group.61
Many patients who were thought to be potentially cur-
able became eligible for palliative advanced stage trials as a 
consequence of the PET scan, and because they usually had a 
smaller quantity of metastatic disease, they improved the sur-
vival of the clinical trials to which they were accrued regard-
less of the treatment arm.
Sex Migration
Female sex is associated with a better OS in advanced 
NSCLC.62 Historically and up until recent years, more males 
are diagnosed with NSCLC than females owing in large part 
to the epidemiology of tobacco smoking. An institutional 
review by Schabath et al.63 showed 64% of patients diagnosed 
with NSCLC from 1986 to 1988 were males, whereas this 
decreased to 49% in the 2006 to 2008 time cohort. This is 
concordant with what is seen in clinical trials. In the 1980s, 
the majority of patients enrolled in NSCLC trials were males. 
More recent trials enrolled a higher number of females. For 
example, 47% of patients in the PointBreak trial were females 
and 46% in ECOG 4599.29 Female sex is a remarkable prog-
nostic factor that is associated with superior survival compared 
with males regardless of the treatment (surgery, radiotherapy, 
or systemic treatment) or stage of disease.62
Better Treatment of Brain Metastases
The proportion of NSCLC patients who develop brain 
metastases has been reported from 24% to 56%.64 The prob-
ability of brain metastases cumulates as a function of time and 
will be greater as patients live longer. Whole brain radiotherapy 
(WBRT) alone has been shown in multiple phase III trials to 
have a median OS of 4.1 to 6.4 months.65–67 The combination of 
WBRT with either surgical resection or stereotactic radiosur-
gery (SRS) in appropriately selected patients has been shown to 
improve OS, local response rates, and allow patients to be func-
tionally independent longer. In the landmark trial by Patchell 
et al.,68 which randomized patients with one brain metastasis 
to receive WBRT with or without an up-front attempt at gross 
total resection, the addition of surgical resection was shown 
to decrease the risk of local recurrence, improve OS (median 
40 vs. 15 wk, p < 0.01), and remain functionally independent 
longer (38 vs. 8 wk, p < 0.005). In the Radiation Therapy 
Oncology Group 9508, randomized clinical trial of WBRT or 
SRS and WBRT in patients with up to three lesions showed 
no signiﬁcant improvement in survival (median OS, 5.7 vs. 
6.5 mo; p = 0.13).69 The prespeciﬁed subgroup of patients 
with one brain metastasis showed an improvement in median 
OS (6.5 vs. 4.9 mo, p = 0.04). However, when the Radiation 
Therapy Oncology Group 9508 patient population was post 
stratiﬁed by a graded prognostic assessment, a subgroup can 
be identiﬁed where WBRT plus SRS is associated with a much 
larger survival beneﬁt (21.0 vs. 10.3 mo; p = 0.05) regardless 
of the number of brain metastases.69
Many modern trials sometimes exclude patients with 
brain metastases, thereby inflating their OS compared with 
older trials with no such restriction. Moreover, appropriately 
selected patients who develop brain metastases on trial and 
receive modern treatment paradigms will show better survival 
outcomes irrespective of the ﬁrst-line chemotherapy and pos-
sibly have more second-line and third-line options available. 
Any thoracic oncologist who has been in practice for many 
years knows that in the era of WBRT only for brain metasta-
ses, 2-year survivors were exceptional, whereas with modern 
treatment paradigms, they are often seen.
Better Palliative Care
Supportive care has dramatically improved since the 
1970s, with more effective therapies for relief of cancer-
related symptoms and a greater focus on patient-related 
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outcomes. Temel et al.70 performed a randomized controlled 
trial evaluating the impact of early palliative care in addition 
to standard oncologic care compared with oncologic care 
alone. Not only did the patients who received early palliative 
care have a better quality of life than patients in the standard 
care arm, but median OS was longer among patients receiving 
early palliative care (11.6 vs. 8.9 mo, p = 0.02). This effect 
is widely accepted and improved palliative care infrastructure 
over time at academic centers conducting clinical trials should 
increase patient survival.
CONCLUSIONS
Over the past 30 years, there has been signiﬁcant 
improvement in survival for advanced NSCLC patients, with 
a doubling of median OS from 7 to 12 to 13 months and 1-year 
survival from 25% to 50% to 55%. The principal conclusion 
of this review is that the contribution of improved ﬁrst-line 
chemotherapy to this gain is small. The statistically signiﬁ-
cant survival superiority reported in pivotal randomized trials 
containing new chemotherapy agents is consistently not con-
ﬁrmed in subsequent randomized trials comparing that regi-
men with other platinum doublets.
The failure to conﬁrm the ﬁnding of a superior regimen 
in subsequent trials deserves special comment as this phe-
nomenon is observed with all of the third-generation agents. 
This disconcerting effect is not unique to chemotherapeutic 
studies for advanced NSCLC as there are increasing concerns 
that most research ﬁndings in any scientiﬁc discipline are not 
reliable. In a thoughtful article titled “Why most published 
research ﬁndings are false,” Ioannidis71 states “In this frame-
work, a research ﬁnding is less likely to be true when the 
studies conducted in a ﬁeld are smaller, when effect sizes are 
smaller, when there is a greater number and lesser preselec-
tion of tested relationships; where there is greater flexibility 
in designs, deﬁnitions, outcomes and analytic modes; when 
there is greater ﬁnancial and other interest and prejudice; and 
when more teams are involved in a scientiﬁc ﬁeld in chase 
of statistical signiﬁcance.” The contention that these issues 
are relevant to clinical trials of chemotherapy for advanced 
NSCLC is unavoidable.
It is not disputed that the modern third-generation che-
motherapy regimens are less toxic than the old ones. This is 
particularly attractive when the patient has limited reserve for 
toxicity and poor PS. The lower toxicity regimens may have 
an advantage of greater treatment delivery ﬁdelity. This may 
make it possible for chemotherapy to be given to a slightly 
larger proportion of the large pool of untreated advanced 
NSCLC patients.
The other reasons for improved survival reported in 
clinical trials of advanced NSCLC should be more consis-
tently acknowledged in reviews of treatment. Some of the 
factors are real improvements in therapy including second-
line/third-line systemic therapy, maintenance therapy, bet-
ter treatment of brain metastases, and better palliative care. 
However, others that make up a large proportion of the gain in 
survival have nothing to do with treatment. PS selection and 
restriction of patients with brain metastases relates to conven-
tions of clinical trial design. Sex migration relates to changes 
in the epidemiology of lung cancer. Stage migration relates to 
application of technology to assign stage.
The spin of the life-death cycle of NSCLC ﬁrst-line che-
motherapy regimens has in all likelihood played out as no new 
platinum doublets are expected to enter large controlled trials. 
Given the limited improvement in the power of ﬁrst-line che-
motherapy over the past 30 years, new approaches to systemic 
treatment must not only show improved efﬁcacy for NSCLC 
patients in clinical trials, but be suitable for the huge unmet 
need of the majority of patients unsuitable for any currently 
available systemic agents.
REFERENCES
 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 
2014;64:9–29.
 2. Canadian Cancer Society's Advisory Committee on Cancer Statistics. 
Canadian Cancer Statistics 2014. Toronto, ON: Canadian Cancer Society, 
May 2014. Available at: http://www.cancer.ca/~/media/cancer.ca/CW/
cancer%20information/cancer%20101/Canadian%20cancer%20statis-
tics/Canadian-Cancer-Statistics-2014--EN.pdf. Accessed September 3, 
2015.
 3. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung 
cancer management. J Clin Oncol 2014;32:973–982.
 4. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in 
addition to supportive care improves survival in advanced non–
small-cell lung cancer: a systematic review and meta-analysis of indi-
vidual patient data from 16 randomized controlled trials. J Clin Oncol 
2008;26:4617–4625.
 5. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in 
patients with advanced non-small-cell lung cancer–report of a Canadian 
multicenter randomized trial. J Clin Oncol 1988;6:633–641.
 6. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical 
Oncology Clinical Practice Guideline update on chemotherapy for stage 
IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251–6266.
 7. Penrod JR, Korytowsky B, Petrilla A, et al. Survival of U.S. Medicare 
patients with advanced non-small cell lung cancer by line of therapy. 
ASCO Meeting Abstracts 2014;32(15 suppl):6582.
 8. Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE. Looking beyond surveil-
lance, epidemiology, and end results: patterns of chemotherapy admin-
istration for advanced non-small cell lung cancer in a contemporary, 
diverse population. J Thorac Oncol 2010;5:1529–1535.
 9. Goulart BH, Reyes CM, Fedorenko CR, et al. Referral and treatment pat-
terns among patients with stages III and IV non-small-cell lung cancer.  
J Oncol Pract 2013;9:42–50.
 10. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of 
referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 
2002;20:1786–1792.
 11. Noonan K, Ho C, Mong Tong K, et al. Referral patterns in advanced non-
small cell lung cancer: impact on delivery of treatment and survival in 
British Columbia. J Thorac Oncol 2013;8:S1179.
 12. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-
small-cell lung cancer: recent developments. Lancet 2013;382:709–719.
 13. Golan T, Urban D, Berger R, Lawrence YR. Changing prognosis of meta-
static colorectal adenocarcinoma: Differential improvement by age and 
tumor location. Cancer 2013;119:3084–3091.
 14. Bitran JD, Desser RK, DeMeester TR, et al. Cyclophosphamide, adriamy-
cin, methotrexate, and procarbazine (CAMP)–effective four-drug combi-
nation chemotherapy for metastatic non-oat cell bronchogenic carcinoma. 
Cancer Treat Rep 1976;60:1225–1230.
 15. Chahinian PA, Arnold DJ, Cohen JM, et al. Chemotherapy for broncho-
genic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and 
lomustine. JAMA 1977;237:2392–2396.
 16. Eagan RT, Ingle JN, Frytak S, et al. Platinum-based polychemotherapy 
versus dianhydrogalactitol in advanced non-small cell lung cancer. 
Cancer Treat Rep 1977;61:1339–1345.
 17. Karnofsky D, Abelmann W, Craver L, et al. The use of nitrogen mustards 
in the palliative treatment of carcinoma with particular reference to bron-
chogenic carcinoma. Cancer 1948;1:634–656.
1530 Copyright © 2015 by the International Association for the Study of Lung Cancer
Noonan et al. Journal of Thoracic Oncology ® • Volume 10, Number 11, November 2015
 18. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bron-
chogenic carcinoma. Am J Med 1969;46:516–525.
 19. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy 
in the treatment of advanced Hodgkin’s disease. Ann Intern Med 
1970;73:881–895.
 20. Anonymous. Chemotherapy in non-small cell lung cancer: a meta-
analysis using updated data on individual patients from 52 randomised 
clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 
1995;311:899–909.
 21. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in 
metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology 
Group Study. J Clin Oncol 1986;4:702–709.
 22. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality 
of life in advanced non-small-cell lung cancer patients treated with two 
dose levels of paclitaxel combined with cisplatin versus etoposide with 
cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin 
Oncol 2000;18:623–631.
 23. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of 
vinorelbine and cisplatin versus vindesine and cisplatin versus vinorel-
bine alone in advanced non-small-cell lung cancer: results of a European 
multicenter trial including 612 patients. J Clin Oncol 1994;12:360–367.
 24. Kubota K, Watanabe K, Kunitoh H, et al.; Japanese Taxotere Lung Cancer 
Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vin-
desine plus cisplatin in patients with stage IV non-small-cell lung cancer: the 
Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254–261.
 25. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin ver-
sus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV 
non-small-cell lung cancer: a phase III randomized study of the London 
Lung Cancer Group. J Clin Oncol 2005;23:142–153.
 26. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology 
Group. Comparison of four chemotherapy regimens for advanced non-
small-cell lung cancer. N Engl J Med 2002;346:92–98.
 27. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing 
cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemother-
apy-naive patients with advanced-stage non-small-cell lung cancer. J Clin 
Oncol 2008;26:3543–3551.
 28. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus 
gemcitabine with either placebo or bevacizumab as ﬁrst-line therapy 
for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 
2009;27:1227–1234.
 29. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone 
or with bevacizumab for non-small-cell lung cancer. N Engl J Med 
2006;355:2542–2550.
 30. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, 
Socinski MA. Third-generation chemotherapy agents in the treatment of 
advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 
2007;2:845–853.
 31. Gofﬁn J, Lacchetti C, Ellis PM, Ung YC, Evans WK; Lung Cancer Disease 
Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 
First-line systemic chemotherapy in the treatment of advanced non-small 
cell lung cancer: a systematic review. J Thorac Oncol 2010;5:260–274.
 32. Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-
cisplatin versus cisplatin-teniposide in patients with advanced non-small-
cell lung cancer. The European Organization for Research and Treatment of 
Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998;16:2133–2141.
 33. Baldini E, Tibaldi C, Ardizzoni A, et al. Cisplatin-vindesine-mitomycin 
(MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-
vinorelbine (CaN) in patients with advanced non-small-cell lung cancer 
(NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer 
Task Force (FONICAP). Br J Cancer 1998;77:2367–2370.
 34. Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized phase III 
study of gemcitabine-cisplatin versus etoposide-cisplatin in the treat-
ment of locally advanced or metastatic non-small-cell lung cancer. J Clin 
Oncol 1999;17:12–18.
 35. Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus 
mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung 
cancer: a randomized phase III study of the Italian Lung Cancer Project. 
J Clin Oncol 1999;17:3522–3530.
 36. Gebbia V, Galetta D, Riccardi F, et al. Vinorelbine plus cisplatin plus vin-
destine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: 
a prospective randomized study. Lung Cancer 2002;37:179–187.
 37. Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial com-
paring cisplatin-etoposide to carboplatin-paclitaxel in advanced or meta-
static non-small cell lung cancer. Ann Oncol 2005;16:1069–1075.
 38. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of 
paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treat-
ment of patients with advanced non–small-cell lung cancer: a Southwest 
Oncology Group trial. J Clin Oncol 2001;19:3210–3218.
 39. Scagliotti GV, De Marinis F, Rinaldi M, et al.; Italian Lung Cancer Project. 
Phase III randomized trial comparing three platinum-based doublets in 
advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–4291.
 40. Smit EF, van Meerbeeck JP, Lianes P, et al.; European Organization 
for Research and Treatment of Cancer Lung Cancer Group. Three-arm 
randomized study of two cisplatin-based regimens and paclitaxel plus 
gemcitabine in advanced non-small-cell lung cancer: a phase III trial of 
the European Organization for Research and Treatment of Cancer Lung 
Cancer Group–EORTC 08975. J Clin Oncol 2003;21:3909–3917.
 41. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III 
study comparing the same dose and schedule of cisplatin plus the same 
schedule of vinorelbine or gemcitabine in advanced non-small cell lung 
cancer. Eur J Cancer 2005;41:81–92.
 42. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cis-
platin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus 
gemcitabine, and cisplatin plus vinorelbine for advanced non-small-
cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 
2007;18:317–323.
 43. Carney DN. Lung cancer–time to move on from chemotherapy. N Engl J 
Med 2002;346:126–128.
 44. Scagliotti G, Hanna N, Fossella F, et al. The differential efﬁcacy of peme-
trexed according to NSCLC histology: a review of two Phase III studies. 
Oncologist 2009;14:253–263.
 45. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the 
Norwegian lung cancer study group: pemetrexed plus carboplatin com-
pared with gemcitabine plus carboplatin as ﬁrst-line chemotherapy in 
advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217–3224.
 46. Rodrigues-Pereira J, Kim JH, Magallanes M, et al. A randomized phase 
3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as 
ﬁrst-line treatment for advanced, nonsquamous non-small cell lung can-
cer. J Thorac Oncol 2011;6:1907–1914.
 47. Bennouna J, Zatloukal P, Krzakowski MJ, et al. Prospective randomized 
phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed 
(Pem) and P in ﬁrst-line metastatic or locally advanced non-small cell 
lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non 
SCC) histologic type: NAVoTRIAL01—Preliminary results. ASCO 
Meeting Abstracts 2012;30(15 Suppl):7575.
 48. Kim Y, Oh I, Kim K, et al. LBA41_PRA randomized phase III study 
of docetaxel plus cisplatin versus pemetrexed plus cisplatin in ﬁrst line 
non-squamous non-small cell lung cancer (NSQ-NSCLC). Ann Oncol 
2014;25(suppl 4):25.
 49. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase 
III study of pemetrexed plus carboplatin and bevacizumab followed by 
maintenance pemetrexed and bevacizumab versus paclitaxel plus car-
boplatin and bevacizumab followed by maintenance bevacizumab in 
patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.  
J Clin Oncol 2013;31:4349–4357.
 50. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: random-
ized, open-label, phase iii study of ﬁrst-line pemetrexed + carboplatin 
followed by maintenance pemetrexed versus paclitaxel + carboplatin + 
bevacizumab followed by maintenance bevacizumab in patients with 
advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 
2014;10:134–142.
 51. Behera M, Pillai RN, Owonikoko TK, et al. Bevacizumab in combina-
tion with taxane versus non-taxane containing regimens for advanced/
metastatic nonsquamous non-small-cell lung cancer: a systematic review. 
J Thorac Oncol 2015;10:1142–1147.
 52. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial 
of docetaxel versus best supportive care in patients with non-small-cell 
lung cancer previously treated with platinum-based chemotherapy. J Clin 
Oncol 2000;18:2095–2103.
 53. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of 
pemetrexed versus docetaxel in patients with non-small-cell lung cancer 
previously treated with chemotherapy. J Clin Oncol 2004;22:1589–1597.
1531Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ® • Volume 10, Number 11, November 2015 Evolution of First-Line Chemotherapy in NSCLC
 54. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer 
Institute of Canada Clinical Trials Group. Erlotinib in previously treated 
non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
 55. Murray N. Reality check for pemetrexed and maintenance therapy in 
advanced non-small-cell lung cancer. J Clin Oncol 2014;32:482–483.
 56. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed 
plus best supportive care (BSC) versus placebo plus BSC: A phase III 
study. J Clin Oncol 2008;26(15_suppl):8011.
 57. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. 
Erlotinib as maintenance treatment in advanced non-small-cell lung can-
cer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet 
Oncol 2010;11:521–529.
 58. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall 
survival results of the phase III study of maintenance pemetrexed ver-
sus placebo immediately after induction treatment with pemetrexed plus 
cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin 
Oncol 2013;31:2895–2902.
 59. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage 
migration and new diagnostic techniques as a source of misleading statis-
tics for survival in cancer. N Engl J Med 1985;312:1604–1608.
 60. Pﬁster DG, Johnson DH, Azzoli CG, et al.; American Society of Clinical 
Oncology. American Society of Clinical Oncology treatment of unresect-
able non-small-cell lung cancer guideline: update 2003. J Clin Oncol 
2004;22:330–353.
 61. Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, selection 
bias, and survival associated with the adoption of positron emission 
tomography among medicare beneﬁciaries with non-small-cell lung can-
cer, 1998–2003. J Clin Oncol 2012;30:2725–2730.
 62. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: 
analysis of the national Surveillance, Epidemiology, and End Results 
database. Chest 2005;127:768–777.
 63. Schabath MB, Thompson ZJ, Gray JE. Temporal trends in demograph-
ics and overall survival of non-small-cell lung cancer patients at Mofﬁtt 
Cancer Center from 1986 to 2008. Cancer Control 2014;21:51–56.
 64. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. 
Incidence proportions of brain metastases in patients diagnosed (1973 
to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin 
Oncol 2004;22:2865–2872.
 65. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: 
ﬁnal results of the ﬁrst two studies by the Radiation Therapy Oncology 
Group. Int J Radiat Oncol Biol Phys 1980;6:1–9.
 66. Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. 
A randomized phase III protocol for the evaluation of misonidazole com-
bined with radiation in the treatment of patients with brain metastases 
(RTOG-7916). Int J Radiat Oncol Biol Phys 1991;20:53–58.
 67. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation ther-
apy with or without stereotactic radiosurgery boost for patients with one 
to three brain metastases: phase III results of the RTOG 9508 randomised 
trial. Lancet 2004;363:1665–1672.
 68. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of sur-
gery in the treatment of single metastases to the brain. N Engl J Med 
1990;322:494–500.
 69. Sperduto PW, Shanley R, Luo X, et al. Secondary analysis of RTOG 9508, 
a phase 3 randomized trial of whole-brain radiation therapy versus WBRT 
plus stereotactic radiosurgery in patients with 1-3 brain metastases; post-
stratiﬁed by the graded prognostic assessment (GPA). Int J Radiat Oncol 
Biol Phys 2014;90:526–531.
 70. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for 
patients with metastatic non-small-cell lung cancer. N Engl J Med 
2010;363:733–742.
 71. Ioannidis JP. Why most published research ﬁndings are false. PLoS Med 
2005;2:e124.
